A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

November 20, 2018

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions

Non-small Cell Lung CancerHead and Neck CancerEsophageal CancerOther Metastatic Solid Tumors

Interventions

DRUG

JAB-3068

25 mg,100 mg

Trial Locations (4)

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

Peking Union Medical College Hospital, Beijing

Beijing Cancer Hospital, Beijing

Chinese PLA Central Hospital, Beijing